Stohl William, Looney R John
Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA.
Clin Immunol. 2006 Oct;121(1):1-12. doi: 10.1016/j.clim.2006.03.010. Epub 2006 May 11.
Autoantibodies have, until recently, been the overriding focus of investigators of autoantibody-associated diseases. Increasing attention is now being paid to B cells, which not only are the producers of autoantibodies but also contribute to autoimmune disease via autoantibody-independent mechanisms. Therapeutic measures that target B cells for depletion are gaining in popularity. In this review, we will focus on two distinct approaches of depleting B cells; one employing a direct-kill approach by engagement of B cell surface CD20 with an anti-CD20 monoclonal antibody (rituximab), and the other employing an indirect starvation approach by neutralization of B lymphocyte stimulator (BLyS), a potent B cell survival factor. Among the systemic immune-based rheumatic disorders, we will focus on rheumatoid arthritis and systemic lupus erythematosus, two disorders for which therapeutic B cell targeting is being intensely investigated.
直到最近，自身抗体一直是自身抗体相关疾病研究者的首要关注焦点。现在，人们越来越关注B细胞，B细胞不仅是自身抗体的产生者，还通过不依赖自身抗体的机制促成自身免疫性疾病。旨在清除B细胞的治疗措施正越来越受欢迎。在本综述中，我们将聚焦于两种不同的清除B细胞的方法；一种是通过抗CD20单克隆抗体（利妥昔单抗）与B细胞表面CD20结合采用直接杀伤方法，另一种是通过中和B淋巴细胞刺激因子（BLyS，一种强大的B细胞存活因子）采用间接饥饿方法。在基于全身免疫的风湿性疾病中，我们将聚焦于类风湿关节炎和系统性红斑狼疮，这两种疾病的B细胞靶向治疗正在深入研究中。
